跳至主要内容
临床试验/NCT00578708
NCT00578708已完成1 期

Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER

Abbott Medical Devices11 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2003年9月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
35
试验地点
11
主要终点
Closure of perimembranous Ventricular Septal Defects

研究概览

简要总结

The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with hemodynamically significant Perimembranous ventricular septal defects

排除标准

  • Patients < 8 kg
  • Supracristal ventricular septal defects
  • Left ventricle to right atrium shunting
  • Prolapse of the aortic valve
  • Right to left shunting through the defect
  • Perimembranous VSD with an aneurysm and multiple shunts which can not be successfully closed with one device
  • Patients with <2mm aortic rim
  • Sepsis (local/generalized)
  • Complex heart lesions such as atrioventricular canal defect or Tetralogy of Fallot.
  • Patients who are ASA intolerant
  • Unable to be followed for the duration of the clinical trial
  • Inability to obtain informed consent

研究组 & 干预措施

1

Experimental

干预措施: AMPLATZER Membranous VSD Occluder (Device)

结局指标

主要结局

Closure of perimembranous Ventricular Septal Defects

时间窗: 5 years

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验